Americans across the nation are stepping up to help one another and fight the coronavirus that is threatening so many of us. Friends and neighbors are donating food, making essential equipment, and watching out for each other. Another possible way to help is for individuals who have successfully recovered from COVID-19 to donate plasma (similar to a blood donation) to help treat others currently fighting the disease.
The Food and Drug Administration (FDA) “is taking the lead on a national effort to facilitate the development of, and access to, two investigational therapies derived from human blood. These are called convalescent plasma and hyperimmune globulin and are antibody-rich blood products made from blood donated by people who have recovered from the virus. The products can be administered to individuals diagnosed with COVID-19. […] Based on prior experience with respiratory viruses and on data that have emerged from China, these products have the potential to lessen the severity or shorten the length of illness caused by COVID-19. The FDA is facilitating access to convalescent plasma for treating COVID-19 using multiple pathways.
|Congressman Wenstrup on Fox 19 discussing plasma donation for COVID-19 patients.
Guidance on Investigational COVID-19 Convalescent Plasma: FDA updated its guidance on investigational COVID-19 convalescent plasma. The updated guidance extends the period of enforcement discretion through the end of February 2021. This extension will allow continued access to convalescent plasma for the treatment of hospitalized COVID-19 patients while blood establishments develop the necessary operating procedures to manufacture the plasma consistent with the EUA. The guidance also includes a new recommendation that authorized COVID-19 convalescent plasma not be collected from individuals who have received an investigational COVID-19 vaccine.
Collecting and Distributing Blood Plasma:
Additional Resources and FAQs
National COVID-19 Convalescent Plasma Coordination:
Local Coverage on Convalescent Plasma: